Skip to content
DataLookout
Menu

Swiss Cancer Institute clinical trial pipeline

Get alerts when Swiss Cancer Institute's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-20

What changed in the last 30 days

5 trials changed in the last 30 days: 1 stopped, 2 with notable changes, 2 with minor changes only.

  1. Notable: salVage · Systemic Therapy Alone and With Local Ablative Treatment for Stage IV Non-Small Cell Lung Cancer Patients Primary endpoint(s) modified Swiss Cancer InstituteNot applicable NCT06114108
  2. Stopped: Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks Trial terminated Swiss Cancer InstitutePhase 3 NCT02051218
  3. Minor: Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) Primary completion pushed from Jul 16, 2026 to Dec 7, 2026 Swiss Cancer InstitutePhase 2 NCT04245514
  4. Minor: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy · MIBC Primary completion date changed from estimate of Jun 2026 to Apr 26, 2026 Swiss Cancer InstitutePhase 2 NCT04630730
  5. Notable: CtDNA and PET-oriented Therapy · DLBCL A Multicenter, Open-label, Phase II Trial Primary completion pushed from Jul 30, 2026 to Jan 30, 2029 Swiss Cancer InstitutePhase 2 NCT04604067
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Active trials by phase

Phase 2
15
Phase 2/3
1
Not charted: 4 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 12

Get alerts when Swiss Cancer Institute's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free